{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:33:21Z","timestamp":1770982401149,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004839.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T00:00:00Z","timestamp":1377043200000}}],"reference-count":171,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004839.pub3","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T12:47:43Z","timestamp":1377089263000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Oral deferiprone for iron chelation in people with thalassaemia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Sheila A","family":"Fisher","sequence":"first","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J","family":"Brunskill","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onima","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Weatherall Institute of Molecular Medicine; Haematopoietic Stem Cell Laboratory; John Radcliffe and Churchill Hospital Oxford UK OX3 9DS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[{"name":"John Radcliffe and Churchill Hospital; Department of Haematology; Old Road Oxford UK OX3 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Roberts","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/10245330701521614","article-title":"Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0002|cit2","first-page":"Abstract 1146","article-title":"Pattern of iron chelation therapy in Egyptian children with beta-thalassaemia: one-year Mansoura University Childrens Hospital experience [abstract]","volume":"92 Suppl 1","author":"Abdelrazik","year":"2007","journal-title":"Haematologica"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004839.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood.V106.11.2698.2698","article-title":"Randomised, prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO [abstract]","volume":"106","author":"Aydinok","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD004839.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"Abstract 557","DOI":"10.1182\/blood.V108.11.557.557","article-title":"A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and Desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassaemia major [abstract]","volume":"108","author":"Aydinok","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD004839.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.11414","article-title":"A randomized, controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassaemia major","volume":"92","author":"Aydinok","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0006|cit6","first-page":"Abstract 515","article-title":"A randomized, controlled, prospective clinical study comparing the combination therapy of deferiprone (L1) and desferrioxamine (DFO) with L1 and DFO monotherapy in patients with thalassaemia major [abstract]","volume":"91 Suppl 12","author":"Manz","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02724272","article-title":"Deferiprone, efficacy and safety","volume":"71","author":"Choudhry","year":"2004","journal-title":"Indian Journal of Pediatrics"},{"issue":"7","key":"10.1002\/14651858.CD004839.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00277-008-0471-2","article-title":"Iron chelation in thalassaemia: combined or monotherapy? The Egyptian experience","volume":"87","author":"El-Beshlawy","year":"2008","journal-title":"Annals of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0009|cit9","first-page":"1241","article-title":"A prospective randomised controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassaemia","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004839.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"Abstract 3611","DOI":"10.1182\/blood.V104.11.3611.3611","article-title":"Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients [abstract]","volume":"104","author":"Galanello","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0011|cit11","first-page":"21","article-title":"Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassaemic children","volume":"41","author":"Gomber","year":"2004","journal-title":"Indian Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03630260600642617","article-title":"A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong","volume":"30","author":"Ha","year":"2006","journal-title":"Hemoglobin"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03630260600642617","article-title":"A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong","volume":"30","author":"Ha","year":"2006","journal-title":"Hemoglobin"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1081\/HEM-120021538","article-title":"Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study","volume":"27","author":"Galia","year":"2003","journal-title":"Hemoglobin"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004839.pub3-BIB0015|cit15","first-page":"34b","article-title":"Evaluatrion of efficacy of LI versus desferrioxamine by clinical randomised multicentric study [abstract]","volume":"94","author":"Maggio","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells, Molecules and Diseases"},{"issue":"11","key":"10.1002\/14651858.CD004839.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"Abstract 3885","DOI":"10.1182\/blood.V112.11.3885.3885","article-title":"Decrease of mortality during deferiprone treatments: results from a large randomised cohort of thalassemia major patients under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies [abstract]","volume":"112","author":"Maggio","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies","volume":"42","author":"Maggio","year":"2009","journal-title":"Blood Cells, Molecules and Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial","volume":"145","author":"Maggio","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03630269.2011.570674","article-title":"Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients","volume":"35","author":"Pantalone","year":"2011","journal-title":"Hemoglobin"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients","volume":"121","author":"Mourad","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0022|cit22","first-page":"101","article-title":"Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassaemia patients","volume":"27","author":"Olivieri","year":"1990","journal-title":"Seminars in Haematology"},{"issue":"8726","key":"10.1002\/14651858.CD004839.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-H","article-title":"Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients","volume":"336","author":"Olivieri","year":"1990","journal-title":"Lancet"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD004839.pub3-BIB0024|cit24","first-page":"51a","article-title":"Effective iron chelation with L1 in patients with thalassemia major: iron balance and dose response studies [abstract]","volume":"174","author":"Olivieri","year":"1989","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1990.tb24324.x","article-title":"Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients","volume":"612","author":"Olivieri","year":"1990","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0026|cit26","unstructured":"ApoPharma Inc US Food and Drug Administration. Oncologic drugs advisory committee briefing document: NDA #21-825 http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/ucm271469.htm 100 1"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0027|cit27","unstructured":"Hackman R Berkovitch M Sher G Brittenham G Koren G Olivieri N Studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in patients with beta-haemoglobinopathies: The Canadian trial [abstract] Proceedings of the 25th Congress of the International Society of Hematology; 1994 April 17-21; Cancun 1994 213"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0028|cit28","first-page":"651a","article-title":"Randomized trial of deferiprone (LI) and deferoxamine (DFO) in thalassemia major [abstract]","volume":"10 Suppl 1","author":"Olivieri N and The Iron Chelation Research Group","year":"1996","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004839.pub3-BIB0030|cit29","first-page":"35b","article-title":"Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassaemia patients during treatment with deferiprone (L1) and deferoxamine (DFO) [abstract]","volume":"94","author":"Olivieri","year":"1999","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004839.pub3-BIB0031|cit30","first-page":"264a","article-title":"Final results of the randomised trial of deferiprone (L1) and deferoxamine (DFO) [abstract]","volume":"90","author":"Olivieri","year":"1997","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004839.pub3-BIB0029|cit31","first-page":"249a","article-title":"First prospective randomised trial of the iron chelators (L1) and deferoxamine [abstract]","volume":"86","author":"Olivieri","year":"1995","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0033|cit33","unstructured":"Pope E Berkovitch M Olivieri N Koren G First prospective randomized trial of subcutaneous deferoxamine and the orally active chelating agent L1 Proceedings of the 96th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1995 March 15-17; San Diego 1995"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1532-429X-13-34","article-title":"Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload","volume":"13","author":"Smith","year":"2011","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0036|cit36","first-page":"655","article-title":"Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients","volume":"12","author":"Tamaddoni","year":"2010","journal-title":"Iranian Red Crescent Medical Journal"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0037|cit37","first-page":"Abstract P451","article-title":"Effect of myocardial iron removal on right ventricular function: insights from a randomized, placebo controlled, double blind trial in thalassemia major [abstract]","volume":"31 Suppl 1","author":"Alpendurada","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Tanner M The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endomethial function in thalassaemia major: a randomised controlled trial using cardiovascular magnetic resonance [abstract] Proceedings of the European Haematology Association 11th Congress 2006 Abstract 0517","DOI":"10.1182\/blood.V106.11.3655.3655"},{"issue":"11","key":"10.1002\/14651858.CD004839.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"Abstract 1770","DOI":"10.1182\/blood.V108.11.1770.1770","article-title":"Improved endothelial function with combined chelation therapy in thalassaemia major [abstract]","volume":"108","author":"Tanner","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD004839.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004839.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"Abstract 3655","DOI":"10.1182\/blood.V106.11.3655.3655","article-title":"A randomized, placebo controlled double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance [abstract]","volume":"106","author":"Tanner","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0042|cit42","unstructured":"Agouzal M Quyou A Practice of iron chelation in the therapeutic center of thalassemia in Morocco [abstract] Vox Sanguinis: 31st International Congress of the International Society of Blood Transfusion in Joint Cooperation with the 43rd Congress of the DGTI; Berlin, Germany 2010 Abstract P-0879"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.1992.tb06441.x","article-title":"Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1","volume":"82","author":"Al-Refaie","year":"1992","journal-title":"British Journal of Haematology"},{"issue":"9332","key":"10.1002\/14651858.CD004839.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000074235","article-title":"Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment (2)","volume":"110","author":"Athanassiou","year":"2003","journal-title":"Acta Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0046|cit46","first-page":"e55","article-title":"Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassaemia patients","volume":"89","author":"Athanassiou-Metaxa","year":"2004","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/10245332.1999.11746432","article-title":"Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassaemia patients chelated with deferoxamine or deferiprone (L1) versus no chelation","volume":"4","author":"Bartfay","year":"1999","journal-title":"Haematology"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00277-012-1480-8","article-title":"Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients","volume":"91","author":"Cassinerio","year":"2012","journal-title":"Annals of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MPH.0b013e318142b51e","article-title":"Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone","volume":"29","author":"Christioforidis","year":"2007","journal-title":"Journal of Paediatric Haematology and Oncology"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1749-6632.1998.tb10478.x","article-title":"A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone","volume":"850","author":"Cohen","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0051|cit51","unstructured":"Diav-Citrin O Atanackovic G Loebstein R Koren G Investigation of variability in response to deferiprone (L1) inpatients with beta-thalassemia major [abstract] Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5-8; San Diego 1997"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/03630260903546445","article-title":"Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study","volume":"34","author":"Drakonaki","year":"2010","journal-title":"Hemoglobin"},{"issue":"11","key":"10.1002\/14651858.CD004839.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"Abstract 3732","DOI":"10.1182\/blood.V108.11.3732.3732","article-title":"Liver status in a cohort of polytransfused b-thalasseamie major (BTM) on long term desferrioxamine (DFO) or Deferiprone (L1) [abstract]","volume":"108","author":"Elalfy","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/clpt.1994.12","article-title":"Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassaemia","volume":"55","author":"Fassos","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0055|cit55","first-page":"299, Abstract 0","article-title":"Cardiac function in thalassaemics on combined deferoxamine and deferiprone therapy","volume":"92","author":"Fragatou","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0056|cit56","unstructured":"Galanello R Doneddu I Dessi C Defraia E Dolci C Leoni G Iron chelation in thalassemia major: Combined treatment with deferiprone (DFP) and desferrioxamine (DFO) [abstract] Proceedings of the BIO IRON World Congress on Iron Metabolism; 2001 August 18-23; Cairns 2001 P78"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Goulas V Kourakli-Symeonidis A Camoutisis C Comparative effects of three iron chelation therapies on the quality of life in Greek patients with homozygous transfusion-dependent beta-thalassemia http:\/\/www.hindawi.com\/isrn\/hematology\/2012\/139862\/cta\/","DOI":"10.5402\/2012\/139862"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004839.pub3-BIB0058|cit58","first-page":"494a","article-title":"When deferiprone and desferrioxamine are combined iron excretion is enhanced [abstract]","volume":"98","author":"Grady","year":"2001","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0059|cit59","first-page":"241a","article-title":"Combinations of desferrioxamine and deferiprone markedly enhance iron excretion [abstract]","volume":"100","author":"Grady","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD004839.pub3-BIB0060|cit60","first-page":"310a","article-title":"Deferiprone: its efficacy relative to that of desferal [abstract]","volume":"88","author":"Grady","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0061|cit61","unstructured":"Hershko C Hoffbrand A Olivieri N Al-Refaie F Tondury P Wonke B International study group on oral iron chelators: Results of long-term deferiprone (LI) therapy [abstract] Proceedings of the 2nd Meeting of the European Haematology Association; 1996 May 29 - Jun 1; Paris 1996 570"},{"issue":"12","key":"10.1002\/14651858.CD004839.pub3-BIB0062|cit62","first-page":"1423","article-title":"Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion","volume":"88","author":"Kattamis","year":"2003","journal-title":"Haematologica"},{"issue":"6612","key":"10.1002\/14651858.CD004839.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.295.6612.1509","article-title":"Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"295","author":"Kontoghiorghes","year":"1987","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2010.05.005","article-title":"Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone","volume":"45","author":"Lai","year":"2010","journal-title":"Blood Cells, Molecules and Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1365-2141.1997.2463064.x","article-title":"Immune function in patients with beta-thalassamia receiving the orally active iron-chelating agent deferiprone","volume":"98","author":"Loebstein","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD004839.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/mutage\/geg014","article-title":"Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study","volume":"18","author":"Marshall","year":"2003","journal-title":"Mutagenesis"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2141.1995.tb05396.x","article-title":"Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone","volume":"91","author":"Nielsen","year":"1995","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0068|cit68","unstructured":"Olivieri N Brittenham G Koren G Reduction in hepatic iron stores with the oral iron chelator L1 inpatients with transfusion-dependent thalassemia and sickle cell disease: First three years of the Canadian trial [abstract] Proceedings of the 35th Annual Meeting and Exposition of the American Society of Hematology; 1993 December 3-7; St. Louis 1993 1238"},{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1034\/j.1600-0609.2003.00071.x","article-title":"Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan","volume":"70","author":"Peng","year":"2003","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0070|cit70","first-page":"20-61; Abstract","article-title":"Deferirpone in patients with beta-thalassamiea major for 4 years in the Chinese population in Taiwan","volume":"34","author":"Peng","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"Abstract 3736","DOI":"10.1182\/blood.V108.11.3736.3736","article-title":"Study of deferiprone or deferoxamine versus combination therapy in iron-loaded thalassaemia patients in Taiwan","volume":"18 Suppl","author":"Peng","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-0609.2005.00587.x","article-title":"Evaluation of the efficacy of oral deferiprone in beta-thalassaemia major by multislice multiecho T2*","volume":"76","author":"Pepe","year":"2006","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0609.2010.01447.x","article-title":"Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study","volume":"85","author":"Ricchi","year":"2010","journal-title":"European Journal of Haematology"},{"issue":"9352","key":"10.1002\/14651858.CD004839.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(03)12221-0","article-title":"Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility","volume":"361","author":"Pierre","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0609.2001.067001030.x","article-title":"Comparison between deferoxamine and deferiprone (L1) in iron-loaded patients","volume":"67","author":"Taher","year":"2001","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction","volume":"10","author":"Tanner","year":"2008","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1079-9796(03)00206-7","article-title":"Deferiprone versus deferoxamine in patients with thalassaemia major: a randomized clinical trial","volume":"32","author":"Tsakok","year":"2004","journal-title":"Blood Cells, Molecules and Diseases"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0078|cit78","first-page":"Abstract 1065","article-title":"Progenitor haemopoietic cells in the peripheral blood of thalassemic patients with desferioxamine or deferiprone chelation therapy [abstract]","volume":"90 Suppl 2","author":"Vlachaki","year":"2005","journal-title":"Hematology"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0609.2006.00773.x","article-title":"Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy","volume":"78","author":"Vlachaki","year":"2007","journal-title":"European Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/03630260600642609","article-title":"Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassaemia major patients","volume":"30","author":"Wang","year":"2006","journal-title":"Hemoglobin"},{"issue":"5","key":"10.1002\/14651858.CD004839.pub3-BIB0081|cit81","first-page":"488","article-title":"Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia","volume":"12","author":"Zareifar","year":"2009","journal-title":"Archives of Iranian Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1532-429X-14-8","article-title":"Effects of combined deferiprone with deferoxamine on right ventricular function in thalassemia major","volume":"14","author":"Alpendurada","year":"2012","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"21","key":"10.1002\/14651858.CD004839.pub3-BIB0083|cit83","first-page":"5158","article-title":"Probing the origin of chelatable iron during deferiprone and combination therapies: insights from plasma NTBI and LPI determinations","volume":"116","author":"Aydinok","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3324\/haematol.2011.056317","article-title":"Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response","volume":"97","author":"Aydinok","year":"2012","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0085|cit85","unstructured":"Badawy S Hassan TH Hesham MAA Badr MA Evaluation of iron chelation therapy in beta-thalassemic patients in Zagazig University Hospital Pediatric Blood and Cancer; Proceedings of the 23rd Annual Meeting of the American Society of Pediatric Hematology\/Oncology, ASPHO, Montreal, Canada 2010 799-800, Poster 124"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0086|cit86","unstructured":"Hassan T Badr M Hesham M Badawy S Evaluation of iron chelation therapy in beta-thalassemia major patients in East Delta of Egypt Haematologica 701, Abstract 1810"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0087|cit87","unstructured":"Evans P Aydinok Y Manz C Porter J Origin of chelatable iron during deferiprone and combination therapies: Insights from plasma NTBI and LPI American Journal of Hematology 2011 9: E84"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0088|cit88","first-page":"46","article-title":"A prospective study for determination of the mean red cell transfusion requirement compared on the basis of iron overload and type of chelation therapy in multiply transfused thalassaemia major patients","volume":"21","author":"Jain","year":"2011","journal-title":"Transfusion Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0089|cit89","first-page":"21","article-title":"Comparative efficacy of deferrioxamine and combination of deferiprone and deferrioxamine on echocardiographic indices in beta thalassemic patients","volume":"14","author":"Kompany","year":"2009","journal-title":"Scientific Journal of Kurdistan University of Medical Sciences"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0090|cit90","first-page":"21; Abstract 53","article-title":"Long-term use of deferiprone enhances significantly the left ventricular ejection function in thalassemia major","volume":"118","author":"Maggio","year":"2011","journal-title":"ASH Annual Meeting Abstracts; 53rd American Society of Hematology (ASH) Annual Meeting, 10-13 December 2011, San Diego, USA"},{"issue":"7","key":"10.1002\/14651858.CD004839.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23219","article-title":"Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalssemia major patients","volume":"87","author":"Maggio","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1179\/102453312X13376952196610","article-title":"The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients","volume":"17","author":"Mirbehbahani","year":"2012","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0093|cit93","unstructured":"Wonke B A randomised controlled prospective trial using Ferriprox versus placebo and conventional intravenous and subcutaneous iron chelation National Research register: N0277104959"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0094|cit94","unstructured":"National Heart Lung and Blood Institute (NHLBI) Combination therapy compared with single-drug therapy in patients with cardiac diseases ClinicalTrials.gov: NCT00115349"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03630269.2011.570674","article-title":"Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients","volume":"35","author":"Pantalone","year":"2011","journal-title":"Hemoglobin"},{"issue":"21","key":"10.1002\/14651858.CD004839.pub3-BIB0096|cit96","first-page":"Abstract","article-title":"Prospective comparison on cardiac and hepatic iron and cardiac function by MR in thalssemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy","volume":"118","author":"Pepe","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Pepe A Meloni A Rossi G Cuccia L D'Ascola GD Santodirocco M Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy http:\/\/www.jcmr-online.com\/content\/pdf\/1532-429X-15-1.pdf 10.1186\/1532-429X-15-1","DOI":"10.1186\/1532-429X-15-1"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0098|cit98","first-page":"805","article-title":"Cardiac iron and function by CMR in thalassemia major patients treated with combined deferiprone and desferrioxamine regimen versus monotherapies: a multi-center, observational and prospective study","volume":"33","author":"Pepe","year":"2012","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD004839.pub3-BIB0099|cit99","first-page":"5164","article-title":"Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy","volume":"116","author":"Pepe","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0100|cit100","first-page":"696 Abstract 17","article-title":"Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy","volume":"95","author":"Pepe","journal-title":"Haematologica, Proceedings of the 15th Congress of the European Hematology Association, Barcelona, Spain"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0101|cit101","first-page":"514-5, Abstract","article-title":"The cardiac effects of desferrioxamine deferiprone combination therapy and desferrioxamine monotherapy in thalassemic patients","volume":"94","author":"Unal","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0102|cit102","unstructured":"Fondazione Franco e Piera Cutino (Sponsors) Sequential deferasirox-deferiprone versus deferasirox or deferiprone multicentre randomized trial EU Clinical Trials Register: 2009-014666-25 2010"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0103|cit103","unstructured":"Akramipoor R The comparative study of incidence of lens opacity between Osfereal and Deferoxamine in major thalassemia Iranian Registry of Clinical Trials: IRCT20110087677N1"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0104|cit104","unstructured":"Mohsen Saleh Elalfy Ain Shams University Study of efficacy, safety of combined deferasirox and deferiprone versus combined deferiprone and desferal in conditions of iron overload ClinicalTrials.gov: NCT01511848"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-4-73","article-title":"The impact of iron overload and its treatment on quality of life: results from a literature review","volume":"4","author":"Abetz","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","article-title":"Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion-dependent thalassaemia: Indian trial","volume":"82","author":"Agarwal","year":"1992","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000205046","article-title":"High incidence of cardiomyopathy in beta-thalassaemia patients receiving transfusion and iron chelation: reversal by intensified chelation","volume":"84","author":"Aldouri","year":"1990","journal-title":"Acta Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD004839.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.12413","article-title":"Practice guidelines for the management of iron overload in thalassemia major and related disorders","volume":"93","author":"Angelucci","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1172\/JCI110787","article-title":"Hepatic lipid peroxidation in vivo in rats with chronic iron overload","volume":"71","author":"Bacon","year":"1983","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0955-3886(00)00092-8","article-title":"The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)","volume":"23","author":"Berdoukas","year":"2000","journal-title":"Transfusion Science"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1749-6632.1998.tb10479.x","article-title":"Survival and disease complications in thalassemia major","volume":"850","author":"Borgna-Pignatti","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"10","key":"10.1002\/14651858.CD004839.pub3-BIB0112|cit112","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004839.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2002-10-3173","article-title":"Deferiprone and hepatic fibrosis","volume":"101","author":"Brittenham","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Caro JJ Huybrechts KF Green TC Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review http:\/\/www.biomedcentral.com\/1471-2326\/2\/4","DOI":"10.1186\/1471-2326-2-4"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD004839.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long term therapy with the oral iron chelator deferiprone profile of the oral iron chelator: a multicentre study","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0140-6736(83)90170-8","article-title":"Ocular toxicity of high-dose intravenous desferrioxamine","volume":"23","author":"Davies","year":"1983","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0119|cit119","unstructured":"Deeks J Higgins J Altman D Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"2-3","key":"10.1002\/14651858.CD004839.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000039759","article-title":"Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting","volume":"104","author":"Vecchio","year":"2000","journal-title":"Acta Haematologica"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD004839.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0022-3476(05)83374-8","article-title":"Prolonged survival in patients with beta-thalassemia major treated with desferrioxamine","volume":"118","author":"Ehlers","year":"1991","journal-title":"Journal of Paediatrics"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/03630269.2010.485080","article-title":"Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review","volume":"34","author":"Evangeli","year":"2010","journal-title":"Hemoglobin"},{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-2141.2003.04297.x","article-title":"Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with thalassaemia major: applicability of SQUID biomagnetic liver susceptometry","volume":"121","author":"Fischer","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD004839.pub3-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450.pub3","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematologica"},{"issue":"25","key":"10.1002\/14651858.CD004839.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJM198606193142514","article-title":"Yersinia sepsis in patients with iron overload treated with deferoxamine","volume":"314","author":"Gallant","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004839.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2007-02-065805","article-title":"Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia","volume":"109","author":"Henter","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0129|cit129","unstructured":"Hider RC Kontoghiorghes G Silver J Stockham MA Pharmaceutically active hydroxypyridones GB patent 21-46989 1984"},{"issue":"11","key":"10.1002\/14651858.CD004839.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD004839.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0132|cit132","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","article-title":"Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients","volume":"91","author":"Hoffbrand","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1990.tb07887.x","article-title":"Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1), I: iron chelation and metabolic studies","volume":"76","author":"Kontoghiorghes","year":"1990","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0165-5876(95)01308-3","article-title":"Sensorineural hearing loss in children with thalassemia major in Northern Greece","volume":"35","author":"Kontzoglou","year":"1996","journal-title":"International Journal of Pediatric Otorhinolaryngology"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0136|cit136","first-page":"47","article-title":"Secondary iron overload","volume":"1","author":"Kushner","year":"2001","journal-title":"Hematology \/ the Education Program of the American Society of Hematology. American Society of Hematology. Education Program"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4038\/cmj.v47i4.3413","article-title":"Experience with the oral iron chelator deferiprone in transfusion-dependent children","volume":"47","author":"Lucas","year":"2002","journal-title":"Ceylon Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2007.06666.x","article-title":"Light and shadows in the iron chelation treatment of haematological diseases","volume":"138","author":"Maggio","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bcmd.2011.07.002","article-title":"Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials","volume":"47","author":"Maggio","year":"2011","journal-title":"Blood Cells, Molecules and Diseases"},{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1365-2141.2008.07122.x","article-title":"Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: systematic review and meta-analysis","volume":"141","author":"Mamtani","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0141|cit141","first-page":"496","article-title":"Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia","volume":"83","author":"Mazza","year":"1998","journal-title":"Haematologica"},{"issue":"9220","key":"10.1002\/14651858.CD004839.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"issue":"17","key":"10.1002\/14651858.CD004839.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMsb020394","article-title":"Academic freedom in clinical research","volume":"347","author":"Nathan","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","article-title":"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions","volume":"107","author":"Neufeld","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD004839.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198604033141402","article-title":"Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions","volume":"314","author":"Olivieri","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004839.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.V79.10.2741.bloodjournal79102741","article-title":"Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia","volume":"79","author":"Olivieri","year":"1992","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD004839.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0148|cit148","first-page":"249a","article-title":"First prospective randomized trial of the iron chelators deferiprone and deferoxamine [abstract]","volume":"86 Suppl 1","author":"Olivieri","year":"1995","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD004839.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199504063321404","article-title":"Iron-chelation therapy with oral deferiprone in patients with thalassemia major","volume":"332","author":"Olivieri","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0150|cit150","first-page":"264a","article-title":"Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]","volume":"90 Suppl 1","author":"Olivieri","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD004839.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"Olivieri","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM199907083410207","article-title":"The beta-thalassemias","volume":"341","author":"Olivieri","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-0609.1999.tb01888.x","article-title":"Deferiprone (L1) associated neutropenia in beta thalassaemia major: an Indian experience","volume":"63","author":"Pati","year":"1999","journal-title":"European Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0609.1988.tb00198.x","article-title":"High dose desferrioxamine as a cause of growth failure in thalassaemic patients","volume":"40","author":"Piga","year":"1988","journal-title":"European Journal of Haematology"},{"issue":"8075","key":"10.1002\/14651858.CD004839.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(78)90968-6","article-title":"Prevention of iron loading in transfusion-dependent thalassaemia","volume":"1","author":"Pippard","year":"1978","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0950-3536(89)80027-7","article-title":"The toxic effects of desferrioxamine","volume":"2","author":"Porter","year":"1989","journal-title":"Balliere's Clinical Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.1989.tb07761.x","article-title":"Desferrioxamine ototoxicity: evaluation of risk factors in thalassamic patients and guidelines for safe dosage","volume":"73","author":"Porter","year":"1989","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/beha.2002.0214","article-title":"Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia","volume":"15","author":"Porter","year":"2002","journal-title":"Best Practice Research in Clinical Haematology"},{"issue":"26","key":"10.1002\/14651858.CD004839.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJM197606242942603","article-title":"Reassessment of the use of desferrioxamine B in iron overload","volume":"294","author":"Propper","year":"1976","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004839.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM197708252970804","article-title":"Continuous subcutaneous administration of deferoxamine in patients with iron overload","volume":"297","author":"Propper","year":"1977","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0162|cit162","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"6","key":"10.1002\/14651858.CD004839.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1445-5994.1993.tb04722.x","article-title":"Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major","volume":"23","author":"Richardson","year":"1993","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004839.pub3-BIB0164|cit164","first-page":"115","article-title":"Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)","volume":"85","author":"Rombos","year":"2000","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0165|cit165","unstructured":"Swedish Orphan Drug International AB Ferriprox (Deferiprone) Summary of Product Charcteristics www. Swedishorphan.com (accessed 2007)"},{"issue":"4","key":"10.1002\/14651858.CD004839.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.1990.tb07915.x","article-title":"L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major","volume":"76","author":"Tondury","year":"1990","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004839.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.1998.00725.x","article-title":"Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients","volume":"101","author":"Tondury","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD004839.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jme.2003.006577","article-title":"Introduction to the Olivieri symposium","volume":"30","author":"Viens","year":"2004","journal-title":"Journal of Medical Ethics"},{"issue":"5","key":"10.1002\/14651858.CD004839.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-01-0306","article-title":"Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia","volume":"100","author":"Wanless","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004839.pub3-BIB0170|cit170","volume-title":"The Thalassaemia Syndromes","author":"Weatherall","year":"2002"},{"issue":"25","key":"10.1002\/14651858.CD004839.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198506203122503","article-title":"Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major","volume":"312","author":"Wolfe","year":"1985","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004839.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:49:06Z","timestamp":1740124146000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004839.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":171,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004839.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]}}}